Recs

1

What Are the Main Threats to AbbVie's Humira?

AbbVie (NYSE: ABBV  ) , which was spun out of health care stalwart Abbott Laboratories (NYSE: ABT  ) at the start of 2013, has beaten the market -- and its former parent company -- by leaps and bounds this year. It reported solid second-quarter results, largely fueled by 16% year-over-year sales growth of its top-selling autoimmune disease drug, Humira, but are there any threats to AbbVie's most important product? In the following video, from The Motley Fool's health-care show Market Checkup, analysts David Williamson and Max Macaluso review the highlights from AbbVie's second-quarter results, discuss the company's dependence on its high-flying blockbuster drug, and explain potential competitive threats to Humira, such as Pfizer's drug Xeljanz.

AbbVie may be beating the market this year, but Motley Fool co-founder David Gardner, founder of the No. 1 growth stock newsletter in the world, has developed a unique strategy for uncovering truly wealth-changing stock picks. And he wants to share it, along with a few of his favorite growth stock superstars, WITH YOU! It's a special 100% FREE report called "6 Picks for Ultimate Growth." So stop settling for index-hugging gains... and click HERE for instant access to a whole new game plan of stock picks to help power your portfolio.


Read/Post Comments (1) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On September 09, 2013, at 2:39 PM, boczernyk wrote:

    Good, balanced talk on AbbVie. Unlike many HepC stock neophytes, talk was correct re ABBV lead in oral HCV drug development, being head-to-head w Gilead in 2014 non-intereferon therapy rollout.Genotype1 is the largest US patient pool by far, s/b enough for both cos. A high-growth biotech, w 3.8%dividend.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2628522, ~/Articles/ArticleHandler.aspx, 7/24/2016 5:07:29 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 18,570.85 53.62 0.29%
S&P 500 2,175.03 9.86 0.46%
NASD 5,100.16 26.26 0.52%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

7/22/2016 4:00 PM
ABT $43.17 Up +0.13 +0.30%
Abbott Laboratorie… CAPS Rating: *****
AMGN $165.67 Up +1.48 +0.90%
Amgen CAPS Rating: ****
AZN $31.13 Up +0.60 +1.97%
AstraZeneca CAPS Rating: ****
CELG $107.52 Up +0.07 +0.07%
Celgene CAPS Rating: *****
JNJ $125.03 Down -0.12 -0.10%
Johnson and Johnso… CAPS Rating: *****
PFE $36.74 Up +0.03 +0.08%
Pfizer CAPS Rating: ****
REGN $391.34 Up +1.82 +0.47%
Regeneron Pharmace… CAPS Rating: ***

Advertisement